INDICATION & LIMITATIONS OF USE

IMLYGIC® (talimogene laherparepvec) is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery...READ MORE

Prescribing Information Medication Guide Indication Important Safety Information References FAQ Downloads Visit Patient Site

Access and Reimbursement

Amgen believes in the importance of access to treatment and may be able to help patients who have concerns about affording IMLYGIC® (talimogene laherparepvec). In this section, you’ll find information about Amgen's access and reimbursement resources, including IMLYGIC® coding and billing information, Amgen SupportPlus, and Amgen SupportPlus Co-Pay program. In addition, this section includes information about referrals to charitable independent co-pay foundations* that may help patients afford their prescribed melanoma medicine.

*Provided through independent charitable patient assistance programs; program eligibility is based on the charity's criteria. Amgen has no control over independent, third-party programs and provides referrals as a courtesy only.

IMLYGIC® billing and coding information

Hospital Outpatient - Billing Information Sheet for IMLYGIC®

Download Now

Physicians Office - Billing Information Sheet for IMLYGIC®

Download Now

Amgen SupportPlus


Amgen Reimbursement Specialists

Connect with an Amgen SupportPlus Representative or schedule a visit with a Amgen Access Specialist.

Patient Resource Guide

Find co-pay and reimbursement resources† for patients with different kinds of insurance, or no insurance at all.

Benefit verification

Submit, store, and retrieve benefit verifications for all your patients currently on an Amgen product.

Amgen Nurse Partners

An Amgen Nurse Partner is a single point of contact who can help patients and caregivers find the resources that are most important to them, so that they can stay focused on their treatment. Nurse Partners are there to support, not replace, your treatment plan and do not provide medical advice or case management services.‡

Co-pay and reimbursement resources

Help patients with insurance benefit verification and put them in touch with programs that may help them afford their prescribed medication, such as Amgen SupportPlus Co-Pay Program or other independent nonprofit organizations.†

Referrals to resources for day-to-day living

Help patients get in touch with independent nonprofit organizations that may provide community resources, local support groups, and counseling services.†

†Provided through independent nonprofit patient assistance programs; program eligibility is based on the nonprofit’s criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

‡Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

 

SEE HOW WE CAN HELP

Call 866-AMG-ASST (1-866-264-2778) Monday to Friday,
9:00 AM to 8:00 PM EST, or visit www.AmgenSupportPlus.com


IMLYGIC® patient brochure

Print a downloadable booklet designed to help patients understand how IMLYGIC® works and what to expect during treatment that also provides information on co-pay assistance and support organizations.

Download Now

Amgen SupportPlus Co-Pay Program for eligible commercially insured patients



The Amgen SupportPlus Co-Pay Program is here to help eligible commercially insured patients pay for their out-of-pocket prescription costs.

  • Pay as little as $0 out-of-pocket for each dose or cycle (excluding Prolia® and EVENITY®)*
  • Can be applied to deductible, co-insurance, and co-payment†
  • No income eligibility requirement

For additional program details please call 1-888-65-STEP1 (1-888-657-8371).

*$25 out-of-pocket cost for each dose of Prolia® (denosumab) and EVENITY® (romosozumab-aqqg) through Amgen SupportPlus.

†Terms, conditions, and program maximums apply. Other restrictions may apply. See the Amgen SupportPlus Co-Pay Program Terms and Conditions for details. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.

For eligible uninsured patients

The Safety Net Foundation

The Amgen Safety Net Foundation is a nonprofit patient assistance program that helps qualifying uninsured patients access Amgen medicines, including IMLYGIC®, at no cost. For more information, visit www.amgensafetynetfoundation.com, or call 1-888-SN-AMGEN (1-888-762-6436).

Other co-pay resources

Independent Co-pay Foundations**

Patients who need assistance with out-of-pocket costs for melanoma medication may be eligible for assistance from an Independent Nonprofit Co-pay Foundation. For contact information or to be referred to an independent co-pay foundation, visit www.AmgenSupportPlus.com, or call 866-AMG-ASST (1-866-264-2778).

**Provided through independent charitable patient assistance programs that set their own eligibility criteria. Amgen has no control over third party programs and provides referrals as a courtesy only.

boxiconboxicon

UNDERSTAND THE STORAGE AND HANDLING REQUIREMENTS FOR IMLYGIC®

Next

IMPORTANT SAFETY INFORMATION

Contraindications
  • Do not administer IMLYGIC® to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy, due to the risk of life-threatening disseminated herpetic infection.
  • Do not administer IMLYGIC® to pregnant patients.
Warnings and Precautions
  • Accidental exposure to IMLYGIC® may lead to transmission of IMLYGIC® and herpetic infection, including during preparation and administration. Health care providers, close contacts, pregnant women, and newborns should avoid direct contact with injected lesions, dressings, or body fluids of treated patients. The affected area in exposed individuals should be cleaned thoroughly with soap and water and/or a disinfectant.
  • Caregivers should wear protective gloves when assisting patients in applying or changing occlusive dressings and observe safety precautions for disposal of used dressings, gloves, and cleaning materials. Exposed individuals should clean the affected area thoroughly with soap and water and/or a disinfectant.
  • To prevent possible inadvertent transfer of IMLYGIC® to other areas of the body, patients should be advised to avoid touching or scratching injection sites or occlusive dressings.
  • Herpetic infections: Herpetic infections (including but not limited to cold sores and herpetic keratitis) and serious cases of disseminated herpetic infections have been reported in IMLYGIC-® treated patients, including fatal disseminated herpetic infection in the immunocompromised patient population. Immunocompromised patients may be at increased risk of life-threatening disseminated herpetic infection. Patients who develop suspicious herpes-like lesions should follow standard hygienic practices to prevent viral transmission.
  • Patients or close contacts with suspected signs or symptoms of a herpetic infection should contact their health care provider to evaluate the lesions. Suspected herpetic lesions should be reported to Amgen at 1-855-IMLYGIC (1-855-465-9442). Patients or close contacts have the option of follow-up testing for further characterization of the infection.
  • IMLYGIC® is sensitive to acyclovir. Acyclovir or other antiviral agents may interfere with the effectiveness of IMLYGIC®. Consider the risks and benefits of IMLYGIC® treatment before administering antiviral agents to manage herpetic infection.
  • Injection Site Complications: Necrosis or ulceration of tumor tissue may occur during IMLYGIC® treatment. Cellulitis and systemic bacterial infection have been reported in clinical studies. Careful wound care and infection precautions are recommended, particularly if tissue necrosis results in open wounds.
  • Impaired healing at the injection site has been reported. IMLYGIC® may increase the risk of impaired healing in patients with underlying risk factors (eg, previous radiation at the injection site or lesions in poorly vascularized areas). If there is persistent infection or delayed healing of the injection site, consider the risks and benefits of continuing treatment.
  • Immune-Mediated events including glomerulonephritis, vasculitis, pneumonitis, worsening psoriasis, and vitiligo have been reported in patients treated with IMLYGIC®. Consider the risks and benefits of IMLYGIC® before initiating treatment in patients who have underlying autoimmune disease or before continuing treatment in patients who develop immune-mediated events.
  • Plasmacytoma at the Injection Site: Plasmacytoma in proximity to the injection site has been reported in a patient with smoldering multiple myeloma after IMLYGIC® administration in a clinical study. Consider the risks and benefits of IMLYGIC® in patients with multiple myeloma or in whom plasmacytoma develops during treatment.
  • Obstructive Airway Disorder: Obstructive airway disorder has been reported following IMLYGIC® treatment. Use caution when injecting lesions close to major airways.
  • Hepatic Hemorrhage from Transcutaneous Intrahepatic Route of Administration: IMLYGIC is not indicated for transcutaneous intrahepatic route of administration. In clinical studies, cases of hepatic hemorrhage resulting in hospitalization and death have been reported in patients receiving transcutaneous intrahepatic IMLYGIC injections
Adverse Reactions
  • The most commonly reported adverse drug reactions (≥ 25%) in IMLYGIC®-treated patients were fatigue, chills, pyrexia, nausea, influenza-like illness, and injection site pain. Pyrexia, chills, and influenza-like illness can occur at any time during IMLYGIC® treatment, but were more frequent during the first 3 months of treatment.
  • The most common Grade 3 or higher adverse reaction was cellulitis.

Please see full Prescribing Information and Medication Guide for IMLYGIC®.

INDICATION

IMLYGIC® is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

Limitations of use: IMLYGIC® has not been shown to improve overall survival or have an effect on visceral metastases.

IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer IMLYGIC® to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy, due to the risk of life-threatening disseminated herpetic infection.

Do not administer IMLYGIC® to pregnant patients.

Warnings and Precautions

Accidental exposure to IMLYGIC® may lead to transmission of IMLYGIC® and herpetic infection, including during preparation and administration. Health care providers, close contacts, pregnant women, and newborns should

Back to Top